Trophic factors therapy in Parkinson's disease

Shilpa Ramaswamy, Katherine E. Soderstrom, Jeffrey H. Kordower

Research output: Chapter in Book/Report/Conference proceedingChapter

57 Scopus citations

Abstract

Parkinson's disease (PD) is a progressive, neurodegenerative disorder for which there is currently no effective neuroprotective therapy. Patients are typically treated with a combination of drug therapies and/or receive deep brain stimulation to combat behavioral symptoms. The ideal candidate therapy would be the one which prevents neurodegeneration in the brain, thereby halting the progression of debilitating disease symptoms. Neurotrophic factors have been in the forefront of PD research, and clinical trials have been initiated using members of the GDNF family of ligands (GFLs). GFLs have been shown to be trophic to ventral mesencephalic cells, thereby making them good candidates for PD research. This paper examines the use of GDNF and neurturin, two members of the GFL, in both animal models of PD and clinical trials.

Original languageEnglish (US)
Title of host publicationNeurotherapy
Subtitle of host publicationProgress in Restorative Neuroscience and Neurology
EditorsJoost Verhaagen, Elly Hol, Inge Huitenga, Jan Wijnholds, Arthur Bergen, Gerald Boer, Dick Swaab
Pages201-216
Number of pages16
DOIs
StatePublished - 2009
Externally publishedYes

Publication series

NameProgress in Brain Research
Volume175
ISSN (Print)0079-6123

Keywords

  • clinical trials
  • GDNF
  • gene therapy
  • glial cell line-derived neurotrophic factor family ligands
  • neurotrophic factors
  • neurturin
  • Parkinson's disease

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint

Dive into the research topics of 'Trophic factors therapy in Parkinson's disease'. Together they form a unique fingerprint.

Cite this